Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2003) 6 P37

SFE2003 Poster Presentations Endocrine tumours and neoplasia (13 abstracts)

Normalisation of serum IGF-I by pegvisomant is not associated with a reduction in median nerve size in patients with active acromegaly

WM Drake 1 , RA Loureira 1 , GM Besser 1 , JP Monson 1 , PJ Trainer 2 , RH Reznek 3 & SA Sohaib 4


1Department of Endocrinology, St Bartholomew's Hospital, London, UK; 2Department of Endocrinology, Christie Hospital, Manchester, UK; 3Department of Radiology, St Bartholomew's Hospital, London, UK; 4Department of Radiology, Royal Marsden Hospital, London, UK.


Carpal tunnel syndrome (CTS) in acromegaly is caused, in part, by median nerve (MN) swelling. Pegvisomant (Peg), a growth hormone receptor (GHR) antagonist, lowers serum insulin-like growth factor-I (IGF-I) concentrations in patients with acromegaly, but serum GH levels rise and Peg is detected by most GH assays. Demonstrating that normalisation of serum IGF-I by Peg is associated with improvement/reversal of the consequences of GH excess is desirable. We documented changes in CT and MN anatomy in a group of 11 patients (6 male, mean age 54+/-11, SD) treated with Peg. With ethical approval, axial T1-weighted MRI of the dominant hand/wrist were performed at baseline (after 2 and 5 weeks washout from octreotide and bromocriptine respectively) and again after a median of 10 months (range 9-15) Peg therapy (median dose 15 mg/d, range 10-20). No patient had symptomatic CTS. Measurements were made of: flattening of the median nerve ratio (FMNR) at the level of hamate (ham) and pisiform (pis); palmar bowing of the flexor retinaculum (PBFR); and MN cross sectional area (CSA) at the ham and pis. Data were compared using Student's paired t test and significance accepted at 5%. Mean serum IGF-I fell from 580+/-200 ng/ml (SD) at baseline to 200+/-69 ng/ml on PEG (p<0.001). Mean CSA (ham and pis) was unchanged over the course of the study (0.15+/-0.06 vs 0.19+/-0.06 cm2, p=0.09; 0.23+/-0.07 vs 0.23+/-0.07 cm2, p=0.83 respectively, SD). CT volume [FMNR (pis) and PBFR] were not statistically different (2.65+/-0.69 vs 2.30+/-0.51, p=0.09; 0.19+/-0.04 vs 0.19+/-0.04 respectively). FMNR (ham) increased on PEG (2.11+/-0.38 vs 2.49+/-0.40, p=0.03). Biochemical control of acromegaly by Peg is not accompanied by demonstrable improvements in CT/MN anatomy on MRI. Possible explanations include lack of sensitivity of the technique; short washout from octreotide and bromocriptine; and no patient had symptomatic CTS.

Volume 6

194th Meeting of the Society for Endocrinology and Society for Endocrinology joint with Diabetes UK Endocrinology and Diabetes Day

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.